UY32634A - Respuesta inmunitaria reforzada en especies aviares - Google Patents

Respuesta inmunitaria reforzada en especies aviares

Info

Publication number
UY32634A
UY32634A UY0001032634A UY32634A UY32634A UY 32634 A UY32634 A UY 32634A UY 0001032634 A UY0001032634 A UY 0001032634A UY 32634 A UY32634 A UY 32634A UY 32634 A UY32634 A UY 32634A
Authority
UY
Uruguay
Prior art keywords
avian species
immune response
reinforced
response reinforced
effective
Prior art date
Application number
UY0001032634A
Other languages
English (en)
Inventor
Abraham Albert
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of UY32634A publication Critical patent/UY32634A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Fodder In General (AREA)

Abstract

La presente invención se refiere a un procedimiento de activación inmunitaria que es eficaz para provocar una respuesta inmunitaria no específica de antígeno en un miembro de la especie aviar. El procedimiento es particularmente eficaz para proteger un miembro de la especie aviar de enfermedades infecciosas y tratar animales afectados con la enfermedad infecciosa.
UY0001032634A 2009-05-14 2010-05-12 Respuesta inmunitaria reforzada en especies aviares UY32634A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17809909P 2009-05-14 2009-05-14

Publications (1)

Publication Number Publication Date
UY32634A true UY32634A (es) 2010-12-31

Family

ID=42357738

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032634A UY32634A (es) 2009-05-14 2010-05-12 Respuesta inmunitaria reforzada en especies aviares

Country Status (35)

Country Link
US (1) US20120064151A1 (es)
EP (2) EP2429581B1 (es)
JP (1) JP5679589B2 (es)
KR (2) KR20170102379A (es)
CN (2) CN104906573A (es)
AR (1) AR076767A1 (es)
AU (1) AU2010246652B2 (es)
BR (1) BRPI1010803A2 (es)
CA (1) CA2761736C (es)
CL (1) CL2011002808A1 (es)
CO (1) CO6460752A2 (es)
CR (1) CR20110595A (es)
DK (2) DK2429581T3 (es)
EC (1) ECSP11011448A (es)
ES (2) ES2808827T3 (es)
HK (1) HK1168032A1 (es)
HR (2) HRP20151117T1 (es)
HU (2) HUE025765T2 (es)
IL (1) IL215900A (es)
LT (1) LT2992899T (es)
MX (1) MX336019B (es)
MY (1) MY162561A (es)
NI (1) NI201100196A (es)
NZ (1) NZ596366A (es)
PE (1) PE20120903A1 (es)
PL (2) PL2992899T3 (es)
PT (2) PT2992899T (es)
RU (1) RU2570732C9 (es)
SI (2) SI2429581T1 (es)
SV (1) SV2011004056A (es)
TW (1) TWI555846B (es)
UA (1) UA106076C2 (es)
UY (1) UY32634A (es)
WO (1) WO2010130374A1 (es)
ZA (1) ZA201107827B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8945590B2 (en) * 2008-03-25 2015-02-03 Juvaris Biotherapeutics, Inc. Enhancement of an immune response by administration of a cationic lipid-DNA complex (CLDC)
NZ612285A (en) * 2010-12-22 2015-09-25 Bayer Ip Gmbh Enhanced immune response in bovine species
JO3733B1 (ar) 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
CN103721253B (zh) * 2014-01-02 2015-06-10 青岛易邦生物工程有限公司 一种禽脑脊髓炎和鸡痘二联活疫苗
AU2015222102B2 (en) * 2014-02-28 2021-08-19 Bayer Animal Health Gmbh Immunostimulatory plasmids
US9814769B2 (en) 2014-09-30 2017-11-14 Qatar University Vaccines against pathogenic Escherichia coli and methods of using the same
US20190233825A1 (en) * 2015-06-26 2019-08-01 Bayer Animal Health Gmbh Methods of modulating cytosolic dna surveillance molecules
KR20180036765A (ko) * 2015-07-31 2018-04-09 바이엘 애니멀 헬스 게엠베하 돼지 종에서의 강화된 면역 응답성
WO2017021242A1 (en) * 2015-07-31 2017-02-09 Bayer Animal Health Gmbh Enhanced immune response in aquatic species
SG11201900710YA (en) 2016-07-26 2019-02-27 Bayer Animal Health Gmbh Increased fertility in bovine species
MX2020006244A (es) * 2017-12-15 2020-09-03 Bayer Animal Health Gmbh Composiciones inmunoestimulantes.
CN114467855A (zh) * 2022-01-14 2022-05-13 广东海大集团股份有限公司 一种多病因气囊炎雏鸡模型的构建方法及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4458630A (en) * 1982-06-22 1984-07-10 The United States Of America As Represented By The Secretary Of Agriculture Disease control in avian species by embryonal vaccination
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5427791A (en) 1992-08-05 1995-06-27 Regents Of The University Of Minnesota Embryonal vaccine against Newcastle disease
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6048535A (en) 1997-06-12 2000-04-11 Regents Of The University Of Minnesota Multivalent in ovo avian vaccine
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
ATE397942T1 (de) * 1999-03-26 2008-07-15 Vical Inc Adjuvanszusammensetzungen zur erhöhung der immunantwort bezüglich polynukleotid-basierenden impfstoffen
WO2001048018A1 (en) * 1999-12-27 2001-07-05 University Of Manitoba Genetic vaccines for the production of chicken egg-yolk antibodies against enterotoxigenic escherichia coli and other pathogens
US20050181035A1 (en) * 2004-02-17 2005-08-18 Dow Steven W. Systemic immune activation method using non CpG nucleic acids
US8945590B2 (en) * 2008-03-25 2015-02-03 Juvaris Biotherapeutics, Inc. Enhancement of an immune response by administration of a cationic lipid-DNA complex (CLDC)

Also Published As

Publication number Publication date
EP2992899A1 (en) 2016-03-09
HUE025765T2 (en) 2016-05-30
PL2992899T3 (pl) 2021-04-06
ZA201107827B (en) 2012-12-27
DK2429581T3 (en) 2015-11-09
LT2992899T (lt) 2020-10-26
RU2011150529A (ru) 2013-06-20
JP2012526734A (ja) 2012-11-01
KR101966989B1 (ko) 2019-04-08
SI2429581T1 (sl) 2015-11-30
HK1168032A1 (zh) 2012-12-21
MX2011011931A (es) 2011-12-06
HRP20151117T1 (hr) 2015-11-20
HRP20201554T1 (hr) 2020-12-11
CN104906573A (zh) 2015-09-16
PT2992899T (pt) 2020-09-21
US20120064151A1 (en) 2012-03-15
EP2992899B1 (en) 2020-07-01
EP2429581B1 (en) 2015-08-05
MY162561A (en) 2017-06-30
NI201100196A (es) 2012-06-06
NZ596366A (en) 2013-12-20
TWI555846B (zh) 2016-11-01
UA106076C2 (uk) 2014-07-25
AU2010246652A1 (en) 2011-11-17
ECSP11011448A (es) 2011-12-30
DK2992899T3 (da) 2020-09-14
CA2761736C (en) 2017-09-26
CN102427827B (zh) 2015-07-22
PL2429581T3 (pl) 2016-01-29
CN102427827A (zh) 2012-04-25
PT2429581E (pt) 2015-11-02
TW201043698A (en) 2010-12-16
RU2570732C2 (ru) 2015-12-10
CO6460752A2 (es) 2012-06-15
AU2010246652B2 (en) 2014-10-02
CA2761736A1 (en) 2010-11-18
IL215900A0 (en) 2012-01-31
SV2011004056A (es) 2012-03-14
EP2429581A1 (en) 2012-03-21
HUE051005T2 (hu) 2021-01-28
RU2570732C9 (ru) 2016-09-10
WO2010130374A1 (en) 2010-11-18
ES2550181T3 (es) 2015-11-05
AR076767A1 (es) 2011-07-06
PE20120903A1 (es) 2012-08-01
CR20110595A (es) 2012-03-09
IL215900A (en) 2017-07-31
ES2808827T3 (es) 2021-03-02
JP5679589B2 (ja) 2015-03-04
KR20170102379A (ko) 2017-09-08
BRPI1010803A2 (pt) 2018-06-12
MX336019B (es) 2016-01-06
KR20120027345A (ko) 2012-03-21
SI2992899T1 (sl) 2020-10-30
CL2011002808A1 (es) 2012-07-13

Similar Documents

Publication Publication Date Title
UY32634A (es) Respuesta inmunitaria reforzada en especies aviares
CO6761354A2 (es) Respuesta inmune potenciada en la especie bovina
CL2017001585A1 (es) Anticuerpos anti-c5 y métodos para su uso
BR112013024574A2 (pt) polipeptídeo, uso, método de tratamento de indivíduos portadores de doenças e método de tratamento de indivíduos que possuem doenças com um polipeptídeo
ECSP15011603A (es) Subunidades de vacunas de inmersión para peces
CR20130568A (es) Familia de toxinas inhibidoras de insectos activas contra insectos hemípteros y/o lepidópteros
GT201200318A (es) Anticuerpos hacia gdf8 humano
ECSP14020644A (es) Anticuerpos dirigidos contra metaloproteinasas de matriz 9
CO2018001840A2 (es) Composiciones biofarmacéuticas que comprenden anticuerpos anti-il-5
BR112014020019A8 (pt) vetores poxvirais recombinantes expressando tanto proteínas da raiva e ox40 e vacinas feitas a partir destes
ECSP14020504A (es) Anticuerpos contra la metaloproteinasa de la matriz 9
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
BR112013032269A2 (pt) implante de mana de silicone que minimiza a concentração de tensão e o método para fabricação do mesmo
CO2018002207A2 (es) Composiciones contra alergia a los gatos
UY36394A (es) Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso.
CO2019001112A2 (es) Anticuerpos con inmunogenicidad baja y usos de estos referencia cruzada a solicitudes relacionadas
BR112014002406A2 (pt) método para promoção de higiene e limpeza
CL2012002654A1 (es) Compuesto de propilmetilfenol o una composicion que lo comprende para tratar septicemia rickettsial salmonidea (srs) y/o enfermedades causadas por la piscirickettsia salmonis.
BR112016015078A2 (pt) método para prevenir ou tratar infecção por vírus influenza a h7n9, uso do anticorpo e composição farmacêutica
MX2017000869A (es) Vacuna emulsionada para obtener formulaciones de inmunoglobulinas igy concentradas; procesos y usos de las mismas.
CL2016001906A1 (es) Vacunas contra el reovirus aviar.
NI201300058A (es) Respuesta inmune potenciada en la especie bovina
BR112013012482A8 (pt) Modelo de desafio para leishmaniose canina por picadas de mosquito-palha
BR112012022680A2 (pt) métodos para proteger um animal um canino contra doença, e, uso de uma vacina contra vírus da influenza canina
NO2022047I1 (no) Formaldehyde inactivated culture of: Salmon Pancreas Disease Virus (SPDV) strain AL V405

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20210226